GWM
NVAX icon

Geneos Wealth Management’s Novavax NVAX Stock Holding History

Geneos Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.27K Hold
984
– – ﹤0.01% 2040
2026
Q1 		$8.01K Hold
984
– – ﹤0.01% 2045
2025
Q4 		$6.61K Hold
984
– – ﹤0.01% 2074
2025
Q3 		$8.53K Hold
984
– – ﹤0.01% 2007
2025
Q2 		$6.2K Hold
984
– – ﹤0.01% 2504
2025
Q1 		$6.31K Hold
984
– – ﹤0.01% 2437
2024
Q4 		$7.91K Hold
984
– – ﹤0.01% 2149
2024
Q3 		$12.4K Hold
984
– – ﹤0.01% 1753
2024
Q2 		$12.5K Hold
984
– – ﹤0.01% 1490
2024
Q1 		$4.7K Hold
984
– – ﹤0.01% 1718
2023
Q4 		$4.72K Hold
984
– – ﹤0.01% 1733
2023
Q3 		$7.12K Sell
984
-250
-20% -$2K ﹤0.01% 1651
2023
Q2 		$9.17K Hold
1,234
– – ﹤0.01% 1597
2023
Q1 		$8.55K Hold
1,234
– – ﹤0.01% 1589
2022
Q4 		$12.7K Hold
1,234
– – ﹤0.01% 1466
2022
Q3 		$22K Sell
1,234
-836
-40% -$36.2K ﹤0.01% 1292
2022
Q2 		$118K Buy
2,070
+261
+14% +$13.5K 0.01% 951
2022
Q1 		$133K Buy
1,809
+1,004
+125% +$89.5K 0.01% 971
2021
Q4 		$115K Buy
805
+425
+112% +$73K ﹤0.01% 1109
2021
Q3 		$69K Hold
380
– – ﹤0.01% 1338
2021
Q2 		$82K Sell
380
-204
-35% -$37.4K ﹤0.01% 1245
2021
Q1 		$138K Buy
584
+254
+77% +$50.6K ﹤0.01% 1150
2020
Q4 		$23K Buy
330
+230
+230% +$24.4K ﹤0.01% 1824
2020
Q3 		$11K Sell
100
-575
-85% -$70K ﹤0.01% 1922
2020
Q2 		$52K Sell
675
-1,075
-61% -$41.1K ﹤0.01% 1198
2020
Q1 		$22K Buy
+1,750
New +$14.8K ﹤0.01% 1475
2019
Q4 		– Sell
-205
Closed -$1K – 2568
2019
Q3 		$1K Hold
205
– – ﹤0.01% 2423
2019
Q2 		$1K Buy
+205
New +$1.61K ﹤0.01% 2427

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Geneos Wealth Management's NVAX Position: Q2 2026 in Review

Geneos Wealth Management held its Novavax (NVAX) position steady in Q2 2026 at 984 shares worth $9.27K. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

Geneos Wealth Management first reported a position in NVAX in Q2 2019 and has held it in 28 quarters since. The position peaked at $138K in Q1 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Geneos Wealth Management held 984 shares of Novavax worth $9.27K as of Q2 2026.
  • Geneos Wealth Management left its Novavax share count unchanged in Q2 2026.
  • Novavax made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2040 holding.
  • Geneos Wealth Management first reported a position in Novavax in Q2 2019 and has held it in 28 quarters since.
  • Geneos Wealth Management's Novavax position peaked at $138K in Q1 2021.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.